Logo
Thursday, 28 March 2024
Friday, 11 Oct 2019 08:30 pm

Strategy of Acquiring Small Firms Has Increased in Narcolepsy Market

The larger firms are adopting the strategy of acquiring small firms to enhance its product portfolio and expand its footprint in different geographies. Additionally various companies are also undergoing other strategic alliances such as acquisitions and others to garner their significance and remain competitive in the market. 

By SMN Bureau

Narcolepsy Market To Account To US$ 4,537.9 Million By 2027 From US$ 2,026.8 Million In 2018. Jazz Pharmaceuticals, Inc., Novartis AG and TEVA Pharmaceuticals Industries - Notable Market Participants in Narcolepsy Market. 

The narcolepsy market is highly competitive in nature with considerable number of players, having a high level of consolidation overall revenue share. Most of the companies operating in the narcolepsy market are present globally and have wide distribution and sales network through partnerships or authorized dealers.

The most notable market participants are Bioprojet, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., Graymark Healthcare, Inc., Arena Pharmaceuticals, Inc., Shire (Acquired by Takeda), Ligand Pharmaceuticals, Inc., Novartis AG, Mylan N.V., and Shionogi Inc. occupying a considerable share of the market owing to their offerings to the market.

The global narcolepsy market accounted to US$ 2,026.8 Mn in 2018 and is expected to grow at a CAGR of 9.5% during the forecast period 2019 – 2027, to account to US$ 4,537.9 Mn by 2027.

Market leaders are involved in extensive research for the development of new drugs and therapeutics with better efficiency and treatment outcomes. For instance, in October 2018, Jazz Pharmaceuticals announced FDA approval of Xyrem (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in pediatric narcolepsy patients.

The larger firms are adopting the strategy of acquiring small firms to enhance its product portfolio and expand its footprint in different geographies. Additionally various companies are also undergoing other strategic alliances such as acquisitions and others to garner their significance and remain competitive in the market. Jazz Pharmaceuticals announced FDA approval of Xyrem (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in pediatric narcolepsy patients. Takeda Pharmaceutical Company Limited acquired Shire plc to expand its geographic footprint and leading position in Japan and the U.S.

Jazz Pharmaceuticals announced FDA acceptance of supplemental new drug application for Xyrem (sodium oxybate) to treat cataplexy and excessive daytime sleepiness in pediatric narcolepsy patients.


SMN Bureau

Smart Market News brings you the stories of adopting innovative solutions and strategies that have been changing the world. Our insights on products, solutions, companies, and adoption of best practices help in understanding the markets better and make smarter decisions.


Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter
© The News and Media Division of The Insight Partners 2024 | All Rights Reserved | Privacy Policy